Carson Wealth (CWM LLC)
ARQT icon

Carson Wealth (CWM LLC)’s Arcutis Biotherapeutics ARQT Stock Holding History

Carson Wealth (CWM LLC)’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$417K Sell
17,702
-4,757
-21% -$121K ﹤0.01% 2141
2025
Q4 		$652K Buy
22,459
+4,342
+24% +$111K ﹤0.01% 1759
2025
Q3 		$342K Buy
18,117
+6,894
+61% +$109K ﹤0.01% 2017
2025
Q2 		$157K Sell
11,223
-108
-1% -$1.51K ﹤0.01% 2372
2025
Q1 		$177K Buy
11,331
+5,333
+89% +$75.1K ﹤0.01% 1998
2024
Q4 		$84K Buy
5,998
+183
+3% +$2K ﹤0.01% 2399
2024
Q3 		$54K Buy
5,815
+1,711
+42% +$16.9K ﹤0.01% 2626
2024
Q2 		$38K Buy
4,104
+4,044
+6,740% +$36.6K ﹤0.01% 2649
2024
Q1 		$1K Buy
+60
New +$448 ﹤0.01% 4065
2023
Q2 		– Sell
-17
Closed – – 4160
2023
Q1 		$0 Buy
+17
New +$246 ﹤0.01% 4029
2022
Q1 		– Sell
-22
Closed – – 3512
2021
Q4 		$0 Buy
+22
New +$438 ﹤0.01% 3482

Other funds holding ARQT

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Carson Wealth (CWM LLC)'s ARQT Position: Q1 2026 in Review

Carson Wealth (CWM LLC) reduced its Arcutis Biotherapeutics (ARQT) stake by 21% in Q1 2026, selling an estimated $121K and leaving 17,702 shares worth $417K. The position accounts for ﹤0.01% of the portfolio, ranked #2141.

Carson Wealth (CWM LLC) first reported a position in ARQT in Q4 2021 and has held it in 11 quarters since. The position peaked at $652K in Q4 2025. 270 funds tracked by Wall St. Rank hold ARQT as of Q1 2026.

  • Carson Wealth (CWM LLC) held 17,702 shares of Arcutis Biotherapeutics worth $417K as of Q1 2026.
  • Carson Wealth (CWM LLC) sold 4,757 Arcutis Biotherapeutics shares in Q1 2026, an estimated $121K.
  • Arcutis Biotherapeutics made up ﹤0.01% of Carson Wealth (CWM LLC)'s portfolio in Q1 2026, its #2141 holding.
  • Carson Wealth (CWM LLC) first reported a position in Arcutis Biotherapeutics in Q4 2021 and has held it in 11 quarters since.
  • Carson Wealth (CWM LLC)'s Arcutis Biotherapeutics position peaked at $652K in Q4 2025.
  • 270 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q1 2026.

Based on Carson Wealth (CWM LLC)'s 13F filing for Q1 2026, filed 14 May 2026.